The estimated Net Worth of Associates, L.L.C.Morenstei... is at least 2.17 百万$ dollars as of 26 December 2018. Associates Morenstei owns over 25,000 units of Molecular Templates Inc stock worth over 2,170,410$ and over the last 6 years Associates sold MTEM stock worth over 0$.
Sign up
Associates Morenstei MTEM stock SEC Form 4 insiders trading
Associates has made over 1 trades of the Molecular Templates Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Associates bought 25,000 units of MTEM stock worth 86,250$ on 26 December 2018.
The largest trade Associates's ever made was buying 25,000 units of Molecular Templates Inc stock on 26 December 2018 worth over 86,250$. On average, Associates trades about 25,000 units every 0 days since 2018. As of 26 December 2018 Associates still owns at least 1,584,241 units of Molecular Templates Inc stock.
You can see the complete history of Associates Morenstei stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Associates Morenstei's mailing address?
Associates's mailing address filed with the SEC is 2, 731 Alexander Rd, Princeton, NJ 08540, USA.
Insiders trading at Molecular Templates Inc
Over the last 7 years, insiders at Molecular Templates Inc have traded over 22,993,582$ worth of Molecular Templates Inc stock and bought 14,744,530 units worth 82,519,716$ . The most active insiders traders include Target N Vbb Biotech Ag Bio...、David Hirsch、Capital Partners Iii, Llc L.... On average, Molecular Templates Inc executives and independent directors trade stock every 47 days with the average trade being worth of 532,718$. The most recent stock trade was executed by Target N Vbb Biotech Ag Bio... on 2 April 2024, trading 250,000 units of MTEM stock currently worth 587,500$.
What does Molecular Templates Inc do?
molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.
What does Molecular Templates Inc's logo look like?
Complete history of Associates Morenstei stock trades at Molecular Templates Inc
Molecular Templates Inc executives and stock owners
Molecular Templates Inc executives and other stock owners filed with the SEC include:
-
Eric Poma,
Chief Executive Officer, Chief Scientific Officer, Director -
Roger Waltzman,
Chief Medical Officer -
Jason Kim,
President, Chief Operating Officer -
Adam Cutler,
Chief Financial Officer, Treasurer, Secretary -
Dr. Eric E. Poma,
CEO, Chief Scientific Officer & Director -
Dr. Roger J. Waltzman M.B.A., M.D.,
Chief Medical Officer -
Jason S Kim,
Pres & COO -
Dr. Roger J. Waltzman,
Chief Medical Officer -
Corazon Sanders,
Independent Director -
Harold Selick,
Chairman of the Board -
Kevin Lalande,
Independent Director -
David Hirsch,
Independent Director -
David Hoffmann,
Independent Director -
Scott Morenstein,
Independent Director -
Jonathan Lanfear,
Independent Director -
Michael Dowd,
Sr. VP of Project & Alliance Management -
Megan C. Filoon,
Gen. Counsel & Sec. -
Dr. Nenad Sarapa M.D., M.S.,
Sr. VP of Clinical Devel. -
Dr. Jen-Sing Liu Ph.D.,
Exec. VP of Manufacturing -
Dr. Erin Willert Ph.D.,
Exec. VP of R&D -
Dr. Jack Higgins Ph.D.,
Exec. VP of Operations & Head of Manufacturing -
Kurt Elster,
Exec. VP of Corp. Devel. -
Sean McLennan,
Sr. VP of Fin., Controller, Interim Principal Accounting Officer, Interim CFO & Treasurer -
Associates, L.L.C.Morenstei...,
-
Target N Vbb Biotech Ag Bio...,
-
Dave Hoffmann,
Director -
Capital Partners Iii, Llc L...,
-
Scott Dcdk Associates, L.L....,
-
Management Services, Llc Cu...,
-
Sean Mc Lennan,
See remarks -
Management Services, Llc Cu...,
-
Gabriela Gruia,
Director -
Maurizio Voi,
Chief Medical Officer